- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04481633
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection (PREPCOV)
Real-life Evaluation of the Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection in Patients Receiving Long-term Treatment for Systemic Lupus Erythematosus and/or Gougerot's Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A pre- or post-exposure treatment strategy has been validated in some infectious diseases. In particular, in HIV infection, this type of prophylactic treatment reduces the rate of infection in at-risk populations. The first studies from Chinese show that in case of immunosuppression or immunosuppressive treatment, whatever the causal pathology, COVID-19 infection is more severe. The present study presents a population of patients with lupus (SLE) or Gougerot's disease (SGD) who are treated for a long time, with Hydroxy-Chloroquine. The protective effect against COVID-19 infection of Hydroxy-Chloroquine compared to populations not exposed to this drug requires to be assessed in patients and their control groups under or without immunosuppressive treatments.
It is hypothesized that long-term treatment with Hydroxy-Chloroquine in SLE or SGD taken in its usual indication before the onset of the pandemic could decrease the number of COVID19 infections and/or the intensity of the disease.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Laurent ALRIC, Pr
- Phone Number: +33 05 61 32 29 09
- Email: alric.l@chu-toulouse.fr
Study Contact Backup
- Name: Gregory PUGNET, Pr
- Phone Number: +33 (0)5 61 77 71 26
- Email: pugnet.g@chu-toulouse.fr
Study Locations
-
-
-
Limoges, France, 87042
- Not yet recruiting
- Limoges university hospital
-
Contact:
- Anne-Laure FAUCHAIS, Pr
- Phone Number: +33 (0)5 55 05 80 61
- Email: mailto:anne-laure.fauchais@unilim.fr
-
Principal Investigator:
- Anne-Laure FAUCHAIS, Pr
-
Sub-Investigator:
- Kim LY, Dr
-
Montpellier, France, 31295
- Not yet recruiting
- Montpellier University Hospital
-
Contact:
- Georges-Philippe PAGEAUX, Pr
- Phone Number: +33 (0)4 67 33 73 81
- Email: mailto:gp-pageaux@chu-montpellier.fr
-
Principal Investigator:
- Georges-Philippe PAGEAUX, Pr
-
Sub-Investigator:
- Stéphanie FAURE, Dr
-
Paris, France, 75651
- Not yet recruiting
- Pitié Salpêtrière Hospital - Hépatologie
-
Contact:
- Pascal LEBRAY, Dr
- Phone Number: +33 01 42 53 05 96
- Email: Pascal.lebray@aphp.fr
-
Principal Investigator:
- Pascal LEBRAY, Dr
-
Sub-Investigator:
- Edouard LARREY, Dr
-
Paris, France, 75651
- Not yet recruiting
- Pitié Salpêtrière Hospital - Médecine interne
-
Contact:
- Patrice CACOUB, Pr
- Phone Number: +33 01 42 17 80 27.
- Email: patrice.cacoub@aphp.fr
-
Sub-Investigator:
- Mathieu VAUTIER, Dr
-
Pessac, France, 33604
- Not yet recruiting
- Haut-Lévêque Hospital - Gastro-entérologie
-
Contact:
- Victor DE LEDINGHEN, Pr
- Phone Number: +33 (0)5 57 65 64 39
- Email: mailto:victor.deledinghen@chu-bordeaux.fr
-
Principal Investigator:
- Victor DE LEDINGHEN, Pr
-
Sub-Investigator:
- Marie IRLES-DEPE, Dr
-
Pessac, France, 33604
- Not yet recruiting
- Haut-Lévêque Hospital - Médecine interne
-
Contact:
- Jean-François VIALLARD, Pr
- Phone Number: +33 (0)5 57 65 64 83
- Email: mailto:jean-francois.viallard@chu-bordeaux.fr
-
Sub-Investigator:
- Estibaliz LAZARO, Pr
-
Toulouse, France, 31059
- Recruiting
- Toulouse University Hospital
-
Contact:
- Dominique CHAUVEAU, Pr
- Phone Number: +33 (0)5 61 32 32 83
- Email: mailto:chauveau.d@chu-toulouse.fr
-
Principal Investigator:
- Dominique CHAUVEAU, Pr
-
Sub-Investigator:
- David RIBES, Dr
-
Toulouse, France, 31027
- Recruiting
- Joseph Ducuing Hospital - Médecine interne
-
Contact:
- Martin MICHAUD, Pr
- Phone Number: +33 (0)5 61 77 34 48
- Email: mailto:mmichaud@hjd.asso.fr
-
Principal Investigator:
- Martin MICHAUD, Pr
-
Sub-Investigator:
- Francis GACHES, Dr
-
Toulouse, France, 31059
- Recruiting
- Toulouse university Hospital - Larrey Dermatologie
-
Contact:
- Carle PAUL, Pr
- Phone Number: +33 (0)5 67 77 81 20
- Email: paul.c@chu-toulouse.fr
-
Principal Investigator:
- Carle PAUL, PR
-
Sub-Investigator:
- Christina LIVIDEANU, DR
-
Toulouse, France, 31059
- Recruiting
- Toulouse University Hospital - Rhumatologie
-
Contact:
- Arnaud CONSTANTIN, Pr
- Phone Number: +33 056177696
- Email: mailto:constantin.a@chu-toulouse.fr
-
Principal Investigator:
- Arnaud CONSTANTIN, Pr
-
Sub-Investigator:
- Adeline RUYSSEN-WITRAND, Pr
-
Toulouse, France, 31059
- Recruiting
- University Hospital of Toulouse - Rangueil Médecine interne
-
Contact:
- Laurent ALRIC, Pr
- Phone Number: +33 05 61 32 35 95
- Email: alric.l@chu-toulouse.fr
-
Contact:
- Gregory PUGNET, Pr
- Phone Number: +33 05 61 77 71 26
- Email: pugnet.g@chu-toulouse.fr
-
Principal Investigator:
- Laurent ALRIC, Pr
-
Sub-Investigator:
- Gregory PUGNET, Pr
-
Toulouse, France, 31059
- Recruiting
- University hospital Toulouse - Purpan Médecine interne
-
Contact:
- Laurent SAILLER, Pr
- Phone Number: +33 0561772278
- Email: sailler.l@chu-toulouse.fr
-
Principal Investigator:
- Laurent SAILLER, Pr
-
Sub-Investigator:
- Guillaume MOULIS, Dr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Group with hydroxychloroquine treatment (HC +):
- LED/SG diagnosed
- Treatment with Hydroxy-Chloroquine in the 3 months before and during the outbreak at COVID 19, at least in December 2019. Patients may have treatment with immunosuppressants in combination with Hydroxy-Chloroquine.
- COVID19 diagnostic questionnaire and available serology result.
Group without hydroxychloroquine treatment (HC-) :
No Hydroxy-Chloroquine intake for more than 12 months
--> HC- without an immunosuppressant
- Viral hepatitis C cured for more than 12 months or primitive bile cholangitis (CBP) whose diagnosis is based on international criteria.
- Non-significant liver fibrosis assessed either by historical histology or by fibroscan with non-significant liver fibrosis Metavir - F3 (at last available examination)
- No Hydroxy-Chloroquine, or immunosuppressants have been taken for more than 12 months.
COVID19 diagnostic questionnaire and COVID19 serology result available.
-->HC- with an immunosuppressant
- Diagnosis of LED/SG according to the CAB criteria revised in 1997 or autoimmune hepatitis according to the international criteria validated in 2008.
- Patients treated with immunosuppressants for at least three months before the start of the pandemic at COVID 19, at least since December 2019.
- COVID19 diagnostic questionnaire and available serology result.
Exclusion Criteria:
- Anti-CD20 or Cyclophosphamide taken during the six months prior to the completion of the COVID 19 serology.
- Refusal of a blood test for antibodies to COVID-19.
- Protected adults
- Pregnant or breastfeeding women.
- Lack of health insurance coverage
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Patient treated with Hydroxy-chloroquine
patients treated with Hydroxy-Chloroquine (HC) with or without immunosuppressants (IS)(HC+ group, n=400)
|
Diagnosis of Covid-19 past infection will be made by serology
COVID 19 Self-Questionnaire
|
OTHER: Patient without treatment with Hydroxy-chloroquine
patients without treatment with Hydroxy-Chloroquine with or without immunosuppressants
|
Diagnosis of Covid-19 past infection will be made by serology
COVID 19 Self-Questionnaire
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of patients with positive anti-COVID19 serology
Time Frame: Day 1
|
Rate of patients with positive anti-COVID19 serology with or without Hydroxy-Chloroquine.
|
Day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of patients with symptomatic or severe (hospitalization) form of infection
Time Frame: Day 1
|
Rate of patients with symptomatic or severe (hospitalization) form of infection.
|
Day 1
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Laurent ALRIC, Pr, University Hospital, Toulouse
Publications and helpful links
General Publications
- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum In: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038.
- Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, Li Y, Hu Z, Zhong W, Wang M. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020 Mar 18;6:16. doi: 10.1038/s41421-020-0156-0. eCollection 2020. No abstract available.
- Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020 Mar 26;382(13):1199-1207. doi: 10.1056/NEJMoa2001316. Epub 2020 Jan 29.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RC31/20/0186
- 2020-A01906-33 (OTHER: N° ID-RCB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on COVID 19 serology
-
Duke UniversityNorth Carolina Department of Health and Human ServicesCompleted
-
Assaf-Harofeh Medical CenterCompleted
-
Hospital St. Joseph, Marseille, FranceUnknown
-
Northwell HealthCompleted
-
Hôpital Européen MarseilleUnknownCovid19 | Virus-HIVFrance
-
Columbia UniversityRecruitingCoronavirus Infection | Covid-19 | CoronavirusUnited States
-
Hôpital Européen MarseilleActive, not recruiting
-
Catholic University of the Sacred HeartCompletedCoronavirus Infection | Pneumonia, Viral | Pneumonia, Bacterial | Obstructive Lung DiseaseItaly
-
Henry Ford Health SystemCompletedHematologic Disorders and Bone Marrow Failure, Hematopoietic Stem Cell Transplantation (HSCT) or Cellular Therapy (CART)United States
-
Bnai Zion Medical CenterRambam Health Care Campus; Hadassah Medical Organization; Rabin Medical Center; Meir Medical Center and other collaboratorsRecruiting